Innoviva Inc has a consensus price target of $15.17, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from EF Hutton, EF Hutton, and Goldman Sachs on May 10, 2023, April 20, 2023, and March 3, 2023. With an average price target of $19.33 between EF Hutton, EF Hutton, and Goldman Sachs, there's an implied 31.61% upside for Innoviva Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
05/10/2023 | INVA | Buy Now | Innoviva | $14.69 | 53.17% | EF Hutton | Constantine Davides | → $22.5 | Reiterates | → Buy | Get Alert |
04/20/2023 | INVA | Buy Now | Innoviva | $14.69 | 53.17% | EF Hutton | Constantine Davides | → $22.5 | Reiterates | → Buy | Get Alert |
03/03/2023 | INVA | Buy Now | Innoviva | $14.69 | -11.5% | Goldman Sachs | Chris Shibutani | $15 → $13 | Maintains | Neutral | Get Alert |
03/03/2023 | INVA | Buy Now | Innoviva | $14.69 | -31.93% | Morgan Stanley | Matthew Harrison | $13 → $10 | Maintains | Underweight | Get Alert |
03/03/2023 | INVA | Buy Now | Innoviva | $14.69 | 53.17% | EF Hutton | Constantine Davides | → $22.5 | Reiterates | → Buy | Get Alert |
01/24/2023 | INVA | Buy Now | Innoviva | $14.69 | -11.5% | Morgan Stanley | Matthew Harrison | $14 → $13 | Maintains | Underweight | Get Alert |
10/13/2022 | INVA | Buy Now | Innoviva | $14.69 | -4.7% | Morgan Stanley | Matthew Harrison | $13 → $14 | Maintains | Underweight | Get Alert |
08/08/2022 | INVA | Buy Now | Innoviva | $14.69 | -11.5% | Morgan Stanley | Matthew Harrison | $12 → $13 | Maintains | Underweight | Get Alert |
07/20/2022 | INVA | Buy Now | Innoviva | $14.69 | 8.92% | Goldman Sachs | Chris Shibutani | → $16 | Initiates | → Neutral | Get Alert |
07/15/2022 | INVA | Buy Now | Innoviva | $14.69 | -18.31% | Morgan Stanley | Matthew Harrison | $13 → $12 | Maintains | Underweight | Get Alert |
04/12/2022 | INVA | Buy Now | Innoviva | $14.69 | -11.5% | Morgan Stanley | Matthew Harrison | $12 → $13 | Maintains | Underweight | Get Alert |
02/23/2022 | INVA | Buy Now | Innoviva | $14.69 | -18.31% | Morgan Stanley | Matthew Harrison | $10 → $12 | Maintains | Underweight | Get Alert |
02/11/2022 | INVA | Buy Now | Innoviva | $14.69 | 90.61% | EF Hutton | Constantine Davides | → $28 | Initiates | → Buy | Get Alert |
The latest price target for Innoviva (NASDAQ: INVA) was reported by EF Hutton on May 10, 2023. The analyst firm set a price target for $22.50 expecting INVA to rise to within 12 months (a possible 53.17% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Innoviva (NASDAQ: INVA) was provided by EF Hutton, and Innoviva reiterated their buy rating.
There is no last upgrade for Innoviva.
There is no last downgrade for Innoviva.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innoviva, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innoviva was filed on May 10, 2023 so you should expect the next rating to be made available sometime around May 10, 2024.
While ratings are subjective and will change, the latest Innoviva (INVA) rating was a reiterated with a price target of $0.00 to $22.50. The current price Innoviva (INVA) is trading at is $14.69, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.